Ascendis Pharma A/S
Ascendis Pharma A/S (ASND) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ASND · as of Mar 31, 2025
Ownership Breakdown
258
Institutional Holders
▲ 31 vs Q4
$10.15B
Total Inst. Value
▲ $1.37B vs Q4
61.78M
Shares Outstanding
freeFloat 99.64%
65.58M
13F Shares Held
▲ 1.41M vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ASND largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
RA CAPITAL MANAGEMENT, L.P. pharmaceutical preparations | 10.28M | 17.13% | 17.13% | $1.60T | May 15, 2025 | ▲ 168.8K |
WESTFIELD CAPITAL MANAGEMENT CO LP pharmaceutical preparations | 5.48M | 9.13% | 9.13% | $854.00B | May 9, 2025 | ▼ 49.0K |
AVORO CAPITAL ADVISORS LLC pharmaceutical preparations | 5.22M | 8.69% | 8.69% | $813.28B | May 15, 2025 | ▲ 114.9K |
FMR LLC pharmaceutical preparations | 4.67M | 7.79% | 7.79% | $728.32B | May 12, 2025 | ▼ 55.7K |
JANUS HENDERSON GROUP PLC pharmaceutical preparations | 4.49M | 7.48% | 7.48% | $693.95B | May 15, 2025 | ▲ 106.6K |
ARTISAN PARTNERS LIMITED PARTNERSHIP pharmaceutical preparations | 4.26M | 7.09% | 7.09% | $663.44B | May 14, 2025 | ▼ 193.8K |
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. pharmaceutical preparations | 3.05M | 5.09% | 5.09% | $475.97B | May 14, 2025 | ▲ 328.3K |
CAPITAL INTERNATIONAL INVESTORS pharmaceutical preparations | 2.87M | 4.79% | 4.79% | $448.07B | May 12, 2025 | ▲ 11.5K |
PRICE T ROWE ASSOCIATES INC /MD/ pharmaceutical preparations | 2.26M | 3.76% | 3.76% | $351.64B | May 14, 2025 | ▼ 27.1K |
MORGAN STANLEY pharmaceutical preparations | 1.90M | 3.17% | 3.17% | $296.68B | May 15, 2025 | ▲ 1.08M |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
24
Increased
+3.53M shares0
New Positions
first time holders24
Decreased
−1.78M shares0
Sold Out
fully exitedNet shares change (top 50)
+1.74M
+3.53M / −1.78M
Net new holders
+0
0 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ASND insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
7
Buy transactions
1
Sell transactions
7.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
SMITH SCOTT THOMAS EVP & Chief Financial Officer | Jun 2, 2026 | Purchase | 100 | $219.00 | $21.9K | 4.4K | Form 4 ↗ |
BIENAIME JEAN JACQUES director | May 29, 2026 | Purchase | 100 | $223.50 | $22.4K | 900 | Form 4 ↗ |
BIENAIME JEAN JACQUES director | May 29, 2026 | Purchase | 200 | $222.30 | $44.5K | 800 | Form 4 ↗ |
BIENAIME JEAN JACQUES director | May 29, 2026 | Purchase | 200 | $223.76 | $44.8K | 600 | Form 4 ↗ |
SMITH SCOTT THOMAS EVP & Chief Financial Officer | May 29, 2026 | Purchase | 250 | $223.32 | $55.8K | 4.3K | Form 4 ↗ |
BIENAIME JEAN JACQUES director | May 26, 2026 | Purchase | 200 | $239.37 | $47.9K | 400 | Form 4 ↗ |
BIENAIME JEAN JACQUES director | May 26, 2026 | Purchase | 200 | $236.24 | $47.2K | 200 | Form 4 ↗ |
JENSEN FLEMMING STEEN See Remarks | May 11, 2026 | Sale | 19,460 | $238.49 | $4.64M | 0 | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Ascendis Pharma A/S (ASND) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 0.36%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Ascendis Pharma A/S is RA CAPITAL MANAGEMENT, L.P., holding approximately 10.28 million shares — equal to 17.13% of outstanding shares — as of March 31, 2025.
A total of 258 institutional investors currently hold ASND stock, with a combined institutional value of approximately $10.15 billion as of the most recent 13F filing period.
Frequently asked questions
ASND ownershipAscendis Pharma A/S (ASND) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is RA CAPITAL MANAGEMENT, L.P. with a 17.13% stake. Company insiders hold 0.36%. Data sourced from SEC Form 13F as of March 31, 2025.